Dr. Peter Anglin interviews Dr. Paolo Ghia about treating Chronic Lymphocytic Leukemia during the COVID-19 pandemic. Dr. Paolo Ghia is a professor in Medical Oncology at the Università Vita-Salute San Raffaele, and Deputy Chairman of the Division of Experimental Oncology, at IRCCS Ospedale San Raffaele, Milano where he is also Head of the Laboratory of B-Cell Neoplasia and Director of the Strategic research program on CLL.
- Are you changing your approach to initiating therapy for Chronic Lymphocytic Leukemia during the pandemic?
- How has COVID affected your therapeutic decision making (for example- type of therapy)?
- How are you thinking about use of monoclonal antibodies (i.e. rituximab and obinutuzumab) in combination with targeted therapies going forward?
- Will your approach with monoclonal antibodies change back to what you were doing before with better control (lower numbers) of COVID?
- How has your practice changed with uptake of virtual care?
- How are you using COVID testing in your Chronic Lymphocytic Leukemia patients?
- For a patient on treatment for CLL who tested positive for SARS-COV2, do you change/modify therapy?
- Has your use of IVIG changed at all?